Prognostic value of the AST/ALT ratio versus bilirubin in patients with cardiogenic shock

• Verfasst von: Schupp, Tobias [VerfasserIn]
• Verfasst von: Rusnak, Jonas [VerfasserIn]
• Verfasst von: Weidner, Kathrin [VerfasserIn]
• Verfasst von: Ruka, Marinela [VerfasserIn]
• Verfasst von: Egner-Walter, Sascha [VerfasserIn]
• Verfasst von: Dudda, Jonas [VerfasserIn]
• Verfasst von: Forner, Jan [VerfasserIn]
• Verfasst von: Bertsch, Thomas [VerfasserIn]
• Verfasst von: Mashayekhi, Kambis [VerfasserIn]
• Verfasst von: Ayoub, Mohamed [VerfasserIn]
• Verfasst von: Akın, Muharrem [VerfasserIn]
• Verfasst von: Kittel, Maximilian [VerfasserIn]
• Verfasst von: Behnes, Michael [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Titel: Prognostic value of the AST/ALT ratio versus bilirubin in patients with cardiogenic shock
• Verf.angabe: Tobias Schupp, Jonas Rusnak, Kathrin Weidner, Marinela Ruka, Sascha Egner-Walter, Jonas Dudda, Jan Forner, Thomas Bertsch, Kambis Mashayekhi, Mohamed Ayoub, Muharrem Akin, Maximilian Kittel, Michael Behnes, Ibrahim Akin
• E-Jahr: 2023
• Jahr: 14 August 2023
• Umfang: 13 S.
• Fussnoten: Gesehen am 21.12.2023
• Titel Quelle: Enthalten in: Journal of Clinical Medicine
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2023
• Band/Heft Quelle: 12(2023), 16, Artikel-ID 5275, Seite 1-13
• ISSN Quelle: 2077-0383
• DOI: doi:10.3390/jcm12165275
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: AST/ALT ratio
• Sach-SW: bilirubin
• Sach-SW: biomarkers
• Sach-SW: cardiogenic shock
• Sach-SW: mortality
• Sach-SW: prognosis
• K10plus-PPN: 187679450X

Abstract

This study investigates the prognostic value of the aspartate-to-alanine aminotransferase ratio (i.e., AST/ALT ratio) and bilirubin in patients with cardiogenic shock (CS). Despite ongoing improvements regarding the treatment of CS patients, invasive care unit (ICU) mortality in CS patients remains unacceptably high. Limited data regarding the prognostic value of the AST/ALT ratio and bilirubin in patients suffering from CS is available. The authors hypothesize the measurement of liver enzymes during the course of CS may be an easy and feasible method to assess right-heart dysfunction and prognosis in patients with CS. Consecutive patients with CS from 2019 to 2021 were included. Blood samples were retrieved from the day of disease onset (day 1), days 2, 3, 4 and 8. The prognostic value of the AST/ALT ratio and bilirubin was tested for 30-day all-cause mortality. Statistical analyses included univariable t-tests, Spearman’s correlations, Kaplan-Meier analyses, as well as multivariable Cox proportional regression analyses. A total of 157 CS patients were included, with an overall rate of all-cause mortality at 30 days of 51%. The median AST/ALT ratio on day 1 was 1.4, and the median bilirubin was 0.63 mg/dL. No association of the baseline AST/ALT ratio (HR = 1.005; 95% CI 0.649-1.558; p = 0.981) and bilirubin (HR = 1.320; 95% CI 0.834-2.090; p = 0.236) with the risk of 30-day all-cause mortality was found. In contrast, the AST/ALT ratio on day 4 was associated with the risk of 30-day all-cause mortality (HR = 2.826; 95% CI 1.227-6.510; p = 0.015), which was still evident after the multivariable adjustment (HR = 2.830; 95% CI 1.054-7.690; p = 0.039). The AST/ALT ratio during the course of ICU hospitalization from day 4—but not the baseline AST/ALT ratio and bilirubin—was associated with an increased risk of 30-day all-cause mortality in CS patients.